Industry news that matters to you.  Learn more

Xention to Characterize Biomarkers for AF Consortium

Reading time: 1 – 2 minutes

Cambridge-based biopharmaceutical company Xention announced yesterday that it is a partner in the new multidisciplinary atrial fibrillation research consortium, the European Network for Translational Research in Atrial Fibrillation (EUTRAF). The consortium has been awarded a 12 million euro grant to engage in atrial fibrillation (AF) research.

Under the agreement, Xention will characterize molecular biomarkers of abnormal function of ion channels known to play a role in atrial fibrillation, to validate newly identified ion channels that may have therapeutic potential in AF, and to identify pharmacological tools to validate such channels.

The consortium consists of academic research groups and industry partners around Europe. Over the next five years, the consortium will focus on improving the diagnosis, prevention and treatment of AF through the application of a highly integrative research approach.

AF is the most common sustained cardiac arrhythmia, occurring in between 1 and 2% of the general population. The prevalence of AF is expected to increase by more than 2 fold over the next 50 years.

Source: Xention